Cyril Martel

Head of Division

Statens Serum Institut

Denmark

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Cyril Martel is the Head of Division at Statens Serum Institut in Denmark. His research primarily focuses on vaccines and cardiovascular health in older adults, as evidenced by his recent articles examining the effectiveness of bivalent RSV and high-dose influenza vaccines. He has contributed significantly to understanding vaccination outcomes for individuals with atherosclerotic cardiovascular disease and heart failure.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (1)

Michael Dalager-Pedersen

Aalborg University

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Cyril Martel

Research Interests

Contact this professor

About

Articles (10)

Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults

Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine

Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trial

High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults

High-Dose vs. Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial

High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial

RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults

Patient-reported outcomes and home-based self-swabs for influenza-like illness events - lessons learned from the 2023/2024 DANFLU-2 Homeswab PRO substudy

Effect of RSV Vaccine on Heart Failure Hospitalizations

Collaborators (1)

Michael Dalager-Pedersen

Make your next move.